The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer

被引:39
作者
Xu, Xia [1 ]
Deng, Fei [2 ]
Lv, Mengmeng [2 ]
Chen, Xiaoxiang [2 ]
机构
[1] Jiangsu Canc Hosp, Dept Chemotherapy, 42 Baiziting St, Nanjing 210009, Jiangsu, Peoples R China
[2] Jiangsu Canc Hosp, Dept Gynecol Oncol, 42 Baiziting St, Nanjing 210009, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
High-grade serous ovarian cancer (HG-SOC); CA-125; Neoadjuvant chemotherapy (NAC); Interval debulking surgery (IDS); Clinical complete response (CCR); PRIMARY CYTOREDUCTIVE SURGERY; DEBULKING SURGERY; CA-125; LEVEL; STATISTICS; SURVIVAL; CARCINOMA; INDICATOR; ONCOLOGY; SOCIETY; BENEFIT;
D O I
10.1007/s00404-016-4256-x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective No consensus exists on the number of chemotherapy cycles to be administered before and after interval debulking surgery (IDS) in patients with advanced stage epithelial ovarian cancer. The present study aims to explore the optimal number of cycles of neoadjuvant chemotherapy (NAC) and post-operation chemotherapy to treat the International Federation of Gynecology and Obstetrics stage IIIc-IV high-grade serous ovarian cancer (HG-SOC). Materials and Methods A total of 129 IIIc-IV stage HGSOC cases were retrospectively analyzed. Cases were comprised of patients who underwent NAC followed by IDS and who achieved clinical complete response (CCR) at the end of primary therapy. Patients were recruited from the Jiangsu Institute of Cancer Research between 1993 and 2013. Optimal IDS-associated factors were explored with logistic regression. The association between progressionfree survival (PFS), overall survival (OS) duration, and covariates was assessed by Cox proportional hazards model and log-rank test. Results The median number of NAC cycle was 3 (range 1-8). CA-125 decreasing kinetics (p = 0.01) was independently associated with optimal IDS. CA-125 decreasing kinetics, optimal IDS, and NAC cycles was independently associated with OS (p < 0.01, p < 0.01, p = 0.03, respectively) and PFS (p < 0.01, p < 0.01, p = 0.04, respectively). The PFS of patients who underwent >= 5 NAC cycles was shorter than those of patients who underwent <5 NAC cycles (12.3 versus 17.2 months). The PFS and OS of patients who underwent < 5 cycles of adjuvant chemotherapy post-IDS were shorter than those of patients who underwent C5 cycles (14.2 and 20.3 versus 21.2 and 28.8 months). Conclusion NAC cycles, CA-125 decreasing kinetics, and optimal debulking are independently associated with the prognosis of patients with advanced stage HG-SOC who underwent NAC/IDS and achieved CCR. The number of administered NAC cycles should not exceed 4.
引用
收藏
页码:451 / 458
页数:8
相关论文
共 44 条
[1]   Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? [J].
Angioli, Roberto ;
Plotti, Francesco ;
Capriglione, Stella ;
Aloisi, Alessia ;
Montera, Roberto ;
Luvero, Daniela ;
Miranda, Andrea ;
Cafa, Ester Valentina ;
Damiani, Patrizio ;
Benedetti-Panici, Pierluigi .
GYNECOLOGIC ONCOLOGY, 2013, 128 (03) :579-583
[2]  
[Anonymous], ARCH GYNECOL OBSTET
[3]   The biology of ovarian cancer: new opportunities for translation [J].
Bast, Robert C., Jr. ;
Hennessy, Bryan ;
Mills, Gordon B. .
NATURE REVIEWS CANCER, 2009, 9 (06) :415-428
[4]   Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience [J].
Bilici, Ahmet ;
Salepci, Taflan ;
Dane, Faysal ;
Gumus, Mahmut ;
Ustaalioglu, Bala Basak Oven ;
Seker, Mesut ;
Salman, Tarik ;
Turan, Cem ;
Unal, Orhan ;
Yaylaci, Mustafa .
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2010, 282 (04) :417-425
[5]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[6]   Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis [J].
Bristow, Robert E. ;
Chi, Dennis S. .
GYNECOLOGIC ONCOLOGY, 2006, 103 (03) :1070-1076
[7]   Cancer statistics: updated cancer burden in China Preface [J].
Chen, Wanqing .
CHINESE JOURNAL OF CANCER RESEARCH, 2015, 27 (01) :1-1
[8]   Annual report on status of cancer in China, 2011 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Zeng, Hongmei ;
Zhang, Siwei ;
He, Jie .
CHINESE JOURNAL OF CANCER RESEARCH, 2015, 27 (01) :2-12
[9]   Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma [J].
Chen, Xiaoxiang ;
Zhang, Jing ;
Zhang, Zhihong ;
Li, Hongxia ;
Cheng, Wenjun ;
Liu, Jinsong .
HUMAN PATHOLOGY, 2013, 44 (11) :2373-2384
[10]   CA-125 Level as a Prognostic Indicator in Type I and Type II Epithelial Ovarian Cancer [J].
Chen, Xiaoxiang ;
Zhang, Jing ;
Cheng, Wenjun ;
Chang, Doo Young ;
Huang, Jianfei ;
Wang, Xuan ;
Jia, Lizhou ;
Rosen, Daniel G. ;
Zhang, Wei ;
Yang, Da ;
Gershenson, David M. ;
Sood, Anil K. ;
Bast, Robert C., Jr. ;
Liu, Jinsong .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (05) :815-822